Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

383

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

December 3, 2024

Study Completion Date

January 15, 2025

Conditions
Major Depressive Disorder
Interventions
DRUG

NMRA-335140

Participants will receive NMRA-335140 at a dose of 80 mg QD, orally

DRUG

Placebo

Placebo will be administered orally

Trial Locations (64)

10036

Neumora Investigator Site, New York

10314

Neumora Investigator Site, Staten Island

11224

Neumora Investigator Site, Brooklyn

11516

Neumora Investigator Site, Cedarhurst

18104

Neumora Investigator Site, Allentown

19063

Neumora Investigator Site, Media

19462

Neumora Investigator Site, Plymouth Meeting

22903

Neumora Investigator Site, Charlottesville

30060

Neumora Investigator Site, Marietta

32256

Neumora Investigator Site, Jacksonville

32607

Neumora Investigator Site, Gainesville

32751

Neumora Investigator Site, Maitland

32801

Neumora Investigator Site, Orlando

33009

Neumora Investigator Site, Hallandale

33016

Neumora Investigator Site, Miami Lakes

33122

Neumora Investigator Site, Miami

33125

Neumora Investigator Site, Miami

33183

Neumora Investigator Site, Miami

33319

Neumora Investigator Site, Lauderhill

33607

Neumora Investigator Site, Tampa

35801

Neumora Investigator Site, Huntsville

38119

Neumora Investigator Site, Memphis

39232

Neumora Investigator Site, Flowood

43210

Neumora Investigator Site, Columbus

44106

Neumora Investigator Site, Cleveland

44125

Neumora Investigator Site, Garfield Heights

45417

Neumora Investigator Site, Dayton

48302

Neumora Investigator Site, Bloomfield Hills

60201

Neumora Investigator Site, Evanston

60555

Neumora Investigator Site, Warrenville

60634

Neumora Investigator Site, Chicago

63304

Neumora Investigator Site, Saint Charles

72211

Neumora Investigator Site-1, Little Rock

Neumora Investigator Site, Little Rock

72712

Neumora Investigator Site, Bentonville

72758

Neumora Investigator Site, Rogers

75235

Neumora Investigator Site, Dallas

76309

Neumora Investigator Site, Wichita Falls

77030

Neumora Investigator Site, Houston

77090

Neumora Investigator Site, Houston

78737

Neumora Investigator Site, Austin

80910

Neumora Investigator Site, Colorado Springs

85012

Neumora Investigator Site, Phoenix

89102

Neumora Investigator Site, Las Vegas

90015

Neumora Investigator Site, Los Angeles

90504

Neumora Investigator Site, Torrance

90706

Neumora Investigator Site, Bellflower

90807

Neumora Investigator Site, Long Beach

91206

Neumora Investigator Site, Glendale

91403

Neumora Investigator Site #1, Sherman Oaks

Neumora Investigator Site, Sherman Oaks

92056

Neumora Investigator Site, Oceanside

92251

Neumora Investigator Site, Imperial

92506

Neumora Investigator Site, Riverside

92591

Neumora Investigator Site, Temecula

92845

Neumora Investigator Site, Garden Grove

92868

Neumora Investigator Site, Orange

94549

Neumora Investigator Site, Lafayette

95124

Neumora Investigator Site, San Jose

98007

Neumora Investigator Site, Bellevue

98201

Neumora Investigator Site, Everett

02116

Neumora Investigator Site, Boston

01844

Neumora Investigator Site, Methuen

02472

Neumora Investigator Site, Watertown

Sponsors
All Listed Sponsors
lead

Neumora Therapeutics, Inc.

INDUSTRY

NCT06029426 - Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Biotech Hunter | Biotech Hunter